Evommune Inc
EVMN18.010USD
-1.680-8.53%
Close 12/12, 16:00（ET）Quotes delayed by 15 min
0.00Market Cap
LossP/E TTM
More Details of Company
Evommune Inc Info
Ticker Symbol- -
Company name- -
IPO date- -
CEO- -
Number of employees- -
Security type- -
Fiscal year-end- -
Address- -
City- -
Stock exchange- -
Country- -
Postal code- -
Phone- -
Website- -
Ticker Symbol- -
IPO date- -
CEO- -
Company Executives of Evommune Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Eugene A. Bauer, M.D.
Dr. Eugene A. Bauer, M.D.
Chief Medical Officer, Director
Chief Medical Officer, Director
286.42K
--
Ms. Janice Drew
Ms. Janice Drew
Executive Vice President - Operations
Executive Vice President - Operations
38.39K
--
Mr. Arthur S. Kirsch
Mr. Arthur S. Kirsch
Independent Director Nominee
Independent Director Nominee
--
--
Ms. Felice Verduyn-van Weegen
Ms. Felice Verduyn-van Weegen
Independent Director
Independent Director
--
--
Mr. Gregory S. Moss, Esq.
Mr. Gregory S. Moss, Esq.
Chief Business and Legal Officer, Corporate Secretary, Chief Compliance Officer
Chief Business and Legal Officer, Corporate Secretary, Chief Compliance Officer
--
--
Dr. Benjamin F. (Ben) McGraw, III
Dr. Benjamin F. (Ben) McGraw, III
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Robert (Rob) Hopfner, Ph.D.
Dr. Robert (Rob) Hopfner, Ph.D.
Independent Director
Independent Director
--
--
Mr. Yuexin Yu
Mr. Yuexin Yu
Director
Director
--
--
Mr. Kyle B. Carver, CPA
Mr. Kyle B. Carver, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Jeegar P. Patel, Ph.D.
Dr. Jeegar P. Patel, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Eugene A. Bauer, M.D.
Dr. Eugene A. Bauer, M.D.
Chief Medical Officer, Director
Chief Medical Officer, Director
286.42K
--
Ms. Janice Drew
Ms. Janice Drew
Executive Vice President - Operations
Executive Vice President - Operations
38.39K
--
Mr. Arthur S. Kirsch
Mr. Arthur S. Kirsch
Independent Director Nominee
Independent Director Nominee
--
--
Ms. Felice Verduyn-van Weegen
Ms. Felice Verduyn-van Weegen
Independent Director
Independent Director
--
--
Mr. Gregory S. Moss, Esq.
Mr. Gregory S. Moss, Esq.
Chief Business and Legal Officer, Corporate Secretary, Chief Compliance Officer
Chief Business and Legal Officer, Corporate Secretary, Chief Compliance Officer
--
--
Dr. Benjamin F. (Ben) McGraw, III
Dr. Benjamin F. (Ben) McGraw, III
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Wed, Dec 10
Updated: Wed, Dec 10
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
EQT Life Sciences
15.64%
Pivotal Bioventure Partners Investment Advisor LLC
10.68%
RA Capital Management, LP
7.01%
Andera Partners S.A.S.
6.02%
SymBiosis II, L.L.C.
4.06%
Other
56.59%
Shareholders
Shareholders
Proportion
EQT Life Sciences
15.64%
Pivotal Bioventure Partners Investment Advisor LLC
10.68%
RA Capital Management, LP
7.01%
Andera Partners S.A.S.
6.02%
SymBiosis II, L.L.C.
4.06%
Other
56.59%
Shareholder Types
Shareholders
Proportion
Venture Capital
34.93%
Corporation
7.93%
Private Equity
6.31%
Individual Investor
4.92%
Other
45.91%
Institutional Shareholding
Updated: Tue, Dec 9
Updated: Tue, Dec 9
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
4
12.40M
41.24%
+12.40M
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
No Data
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Evommune Inc?
The top five shareholders of Evommune Inc are:
What are the top three shareholder types of Evommune Inc?
The top three shareholder types of Evommune Inc are:
EQT Life Sciences
Pivotal Bioventure Partners Investment Advisor LLC
RA Capital Management, LP
EQT Life Sciences
Pivotal Bioventure Partners Investment Advisor LLC
RA Capital Management, LP
How many institutions hold shares of Evommune Inc (EVMN)?
As of 2025Q4, 4 institutions hold shares of Evommune Inc, with a combined market value of approximately 12.40M, accounting for 41.24% of the total shares. Compared to --, institutional shareholding has increased by --.
What is the biggest source of revenue for Evommune Inc?
In --, the -- business generated the highest revenue for Evommune Inc, amounting to -- and accounting for --% of total revenue.
